Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOPE-PEDF-azobenzene-liposome
- Development stage
- Preclinical
- Lead developer
- Greenwich High School
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic, Topical
01
Overview
DOPE-PEDF-azobenzene-liposome (DPAL) is an experimental, non-invasive topical ocular drug delivery system designed to treat age-related macular degeneration (AMD). Developed as a high school research project, DPAL consists of liposomes loaded with pigment epithelium-derived factor (PEDF), encapsulated with the fusogenic lipid dioleoylphosphatidylethanolamine (DOPE), and embedded with the photoswitchable molecule azobenzene. The liposomes are further modified with kainate and glutamate ligands to target bipolar cells, and the GALA peptide to enhance fusogenic properties. Delivered via a microneedle-embedded contact lens, the system aims to slow retinal degeneration through the neurotrophic effects of PEDF while restoring lost vision using azobenzene as a photoswitchable substitute for lost photoreceptors.
- Other names
- DOPE-PEDF-azobenzene-liposomesDPAL
02
Targets
PEDF (Pigment epithelium-derived factor)Kainate-type ionotropic glutamate receptor
Beyond the preview
Go deeper on DOPE-PEDF-azobenzene-liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOPE-PEDF-azobenzene-liposome.